048410.KQ
Latest Trade
47,150.00KRWChange
-1,300.00(-2.68%)Volume
2,606,102Today's Range
-
50,600.0052 Week Range
-
66,300.00As of on the KOSDAQ ∙ Minimum 15 minute delay
Previous Close | 48,450.00 |
|---|---|
Open | 49,500.00 |
Volume | 2,606,102 |
3M AVG Volume | 138.13 |
Today's High | 50,600.00 |
Today's Low | 46,900.00 |
52 Week High | 66,300.00 |
52 Week Low | 9,470.00 |
Shares Out (MIL) | 36.16 |
Market Cap (MIL) | 1,704,844.00 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19
Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem
Hyundai IBT to change co name to Hyundai Bioscience
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Industry
Personal & Household Prods.
Contact Info
106, Apogongdan-Gil, Apo-Eup
39670
South Korea
+82.54.4306425
http://www.hyundaibioscience.com/Executive Leadership
Sang Gi Oh
Chief Executive Officer, Director
Je Man Jang
Chief Operating Officer, Vice President, Director
Yeong Gwon Jung
Assistant Managing Director
Chang Hyeon Lee
Assistant Managing Director
Jong Sik Park
Internal Auditor
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 93.29 |
Price To Book (MRQ) | 28.81 |
Price To Cash Flow (TTM) | 967.79 |
Total Debt To Equity (MRQ) | 60.08 |
LT Debt To Equity (MRQ) | 46.76 |
Return on Investment (TTM) | -2.96 |
Return on Equity (TTM) | -2.53 |
South Korean firm SK Bioscience Co Ltd shares rocketed 30% on their first day of trading on Thursday, as investor bets on the COVID-19 vaccine developer and maker's prospects turned it into a nearly $12 billion business.
South Korean vaccine developer SK Bioscience Co Ltd is expected to raise 1.5 trillion won ($1.33 billion) in the country's largest IPO since 2017, after pricing the listing at the top of an indicative range, it said on Monday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.